New progress on diagnosis and treatment of anorectal malignant melanoma

Abstract

Zhang Ruizhi, Chen Xin, Zhang Peng, Tao Kaixiong. New progress on diagnosis and treatment of anorectal malignant melanoma[J]. Journal of International Oncology, 2020, 47(6): 377-380.

References30

[1]	Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma[J]. Lancet, 2018,392(10151):971-984. DOI: 10.1016/S0140-6736(18)31559-9. doi:10.1016/S0140-6736(18)31559-9pmid:30238891
[2]	Fields AC, Goldberg J, Senturk J, et al. Contemporary surgical management and outcomes for anal melanoma: a national cancer database analysis[J]. Ann Surg Oncol, 2018,25(13):3883-3888. DOI: 10.1245/s10434-018-6769-y. doi:10.1245/s10434-018-6769-ypmid:30209727
[3]	Naqvi J, Lee A, Lederman A, et al. Patterns of care and survival outcomes in the treatment of anal melanoma[J]. J Gastrointest Cancer, 2020,51(1):211-216. DOI: 10.1007/s12029-019-00238-5. doi:10.1007/s12029-019-00238-5pmid:30982929
[4]	Ren M, Lu Y, Lv J, et al. Prognostic factors in primary anorectal melanoma: a clinicopathological study of 60 cases in China[J]. Hum Pathol, 2018,79:77-85. DOI: 10.1016/j.humpath.2018.05.004. doi:10.1016/j.humpath.2018.05.004pmid:29763716
[5]	Nam S, Kim CW, Baek SJ, et al. The clinical features and optimal treatment of anorectal malignant melanoma[J]. Ann Surg Treat Res, 2014,87(3):113-117. DOI: 10.4174/astr.2014.87.3.113. doi:10.4174/astr.2014.87.3.113
[6]	Manabe S, Boku Y, Takeda M, et al. Endoscopic submucosal dissection as excisional biopsy for anorectal malignant melanoma: a case report[J]. World J Clinl Cases, 2019,7(13):1652-1659. DOI: 10.12998/wjcc.v7.i13.1652.
[7]	Keraliya AR, Krajewski KM, Braschi-Amirfarzan M, et al. Extracutaneous melanomas: a primer for the radiologist[J]. Insights Imaging, 2015,6(6):707-717. DOI: 10.1007/s13244-015-0427-8. doi:10.1007/s13244-015-0427-8pmid:26334521
[8]	Park HJ, Kim HJ, Park SH, et al. JOURNAL CLUB: primary anorectal melanoma: MRI findings and clinicopathologic correlations[J]. AJR Am J Roentgenol, 2018,211(2):W98-W108. DOI: 10.2214/AJR.17.18807. doi:10.2214/AJR.17.18807pmid:29927334
[9]	Wang S, Sun S, Liu X, et al. Endoscopic diagnosis of primary anorectal melanoma[J]. Oncotarget, 2017,8(30):50133-50140. DOI: 10.18632/oncotarget.15495. doi:10.18632/oncotarget.15495pmid:28412758
[10]	Zou S, Cheng Z, Song S, et al. Anal malignant melanoma manifesting hepatic metastases shown on FDG PET/CT[J]. Clin Nucl Med, 2018,43(5):386-388. DOI: 10.1097/RLU.000000000000-2056. doi:10.1097/RLU.0000000000002056pmid:29517546
[11]	Falch C, Mueller S, Kirschniak A, et al. Anorectal malignant melanoma: curative abdominoperineal resection: patient selection with¹⁸F-FDG-PET/CT[J]. World J Surg Oncol, 2016,14(1):185. DOI: 10.1186/s12957-016-0938-x. doi:10.1186/s12957-016-0938-xpmid:27422527
[12]	Valpione S, Gremel G, Mundra P, et al. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients[J]. Eur J Cancer, 2018,88:1-9. DOI: 10.1016/j.ejca.2017.10.029. doi:10.1016/j.ejca.2017.10.029pmid:29175734
[13]	Chen H, Cai Y, Liu Y, et al. Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: a population-based SEER analysis[J]. Medicine (Baltimore), 2016,95(7):e2770. DOI: 10.1097/MD.0000000000002770. doi:10.1097/MD.0000000000002770
[14]	Ford MM, Kauffmann RM, Geiger TM, et al. Resection for anal melanoma: is there an optimal approach?[J]. Surgery, 2018,164(3):466-472. DOI: 10.1016/j.surg.2018.05.026. doi:10.1016/j.surg.2018.05.026pmid:30041967
[15]	Matsuda A, Miyashita M, Matsumoto S, et al. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review[J]. Ann Surg, 2015,261(4):670-677. DOI: 10.1097/SLA.0000000000000862. doi:10.1097/SLA.0000000000000862pmid:25119122
[16]	Del Vecchio M, Di Guardo L, Ascierto PA, et al. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma[J]. Eur J Cance, 2014,50(1):121-127. DOI: 10.1016/j.ejca.2013.09.007.
[17]	Mignard C, Deschamps Huvier A, Gillibert A, et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma[J]. J Oncol, 2018,2018:1908065. DOI: 10.1155/2018/1908065. doi:10.1155/2018/1908065pmid:30631354
[18]	Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma[J]. Cancer, 2016,122(21):3354-3362. DOI: 10.1002/cncr.30259. doi:10.1002/cncr.30259pmid:27533633
[19]	Dodds TJ, Wilmott JS, Jackett LA, et al. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases[J]. Pathology, 2019,51(1):39-45. DOI: 10.1016/j.pathol.2018.09.060. doi:10.1016/j.pathol.2018.09.060pmid:30497801
[20]	Sakaizawa K, Ashida A, Uchiyama A, et al. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients[J]. J Dermatol Sci, 2015,80(1):33-37. DOI: 10.1016/j.jdermsci.2015.07.012. doi:10.1016/j.jdermsci.2015.07.012pmid:26282084
[21]	Gong HZ, Zheng HY, Li J. The clinical significance of KIT mutations in melanoma: a meta-analysis[J]. Melanoma Res, 2018,28(4):259-270. DOI: 10.1097/CMR.0000000000000454. doi:10.1097/CMR.0000000000000454pmid:29746316
[22]	Cinotti E, Chevallier J, Labeille B, et al. Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases[J]. J Eur Acad Dermatol Venereology, 2017,31(11):1834-1840. DOI: 10.1111/jdv.14353.
[23]	Schaefer T, Satzger I, Gutzmer R. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: a retrospective analysis of 75 patients[J]. Medicine (Baltimore), 2017,96(1):e5753. DOI: 10.1097/MD.0000000000005753. doi:10.1097/MD.0000000000005753
[24]	Wei X, Mao L, Chi Z, et al. Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study[J]. Oncol Res, 2019,27(4):495-501. DOI: 10.3727/096504018X-15331163433914. doi:10.3727/096504018X15331163433914pmid:30075827
[25]	Buchbinder EI, Sosman JA, Lawrence DP, et al. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma[J]. Cancer, 2015,121(22):4007-4015. DOI: 10.1002/cncr.29622. doi:10.1002/cncr.29622pmid:26264378
[26]	Kalinsky K, Lee S, Rubin KM, et al. A phase 2 trial of dasatinib in patients with locally advanced or stage Ⅳ mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607)[J]. Cancer, 2017,123(14):2688-2697. DOI: 10.1002/cncr.30663. doi:10.1002/cncr.30663pmid:28334439
[27]	Alrwas A, Papadopoulos NE, Cain S, et al. Phase Ⅰ trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma[J]. Melanoma Res, 2014,24(4):342-348. DOI: 10.1097/CMR.0000000000000062. doi:10.1097/CMR.0000000000000062
[28]	Heppt MV, Roesch A, Weide B, et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma[J]. Eur J Cancer, 2017,81:36-44. DOI: 10.1016/j.ejca.2017.05.014. doi:10.1016/j.ejca.2017.05.014pmid:28600969
[29]	Cui C, Lian B, Zhou L, et al. Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients[J]. Ann Surg Oncol, 2018,25(8):2184-2192. DOI: 10.1245/s10434-018-6503-9. doi:10.1245/s10434-018-6503-9pmid:29748886
[30]	Chae WY, Lee JL, Cho DH, et al. Preliminary suggestion about staging of anorectal malignant melanoma may be used to predict prognosis[J]. Cancer Res Treat, 2016,48(1):240-249. DOI: 10.4143/crt.2014.305. doi:10.4143/crt.2014.305pmid:25761474

New progress on diagnosis and treatment of anorectal malignant melanoma

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References30

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[6]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[7]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[8]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[9]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[10]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[11]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng.Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor[J]. Journal of International Oncology, 2024, 51(5): 298-302.
[12]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[13]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[14]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[15]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.